Information Provided By:
Fly News Breaks for November 15, 2019
AMRN
Nov 15, 2019 | 07:17 EDT
Stifel analyst Derek Archila reiterated his Buy rating on Amarin shares after advisors to the FDA unanimously voted to support the expansion of Vascepa's label but was "relatively split" on including primary prevention as an indication, stating that he thinks shares "should trade to the mid-$20 range on the news." The key question now is whether or not Vascepa will receive a broader label, inclusive of primary prevention patients, said Archila. Vascepa approval in secondary prevention alone offers an addressable market of at least 10M-15M patients, estimates Archila, who maintains a $3B peak sales estimate for the drug. The company and the FDA will now have label discussions ahead of Vascepa's PDUFA on December 28, noted the analyst. At time of writing in pre-market trading, Amarin shares are flat at $21.49.
News For AMRN From the Last 2 Days
There are no results for your query AMRN